fda warning letter bpc-157 2023 panel narrowly backs unapproved peptide drugs – NBC4 Washington FDA Moves to Reevaluate Several

doi:10.1111/jop.13165 Tregoning JS, Russell RF, Kinnear E

Our formulations are compounded by licensed pharmacies with clinician oversight

Items included in the packaged payment provided in conjunction with the primary service also include all drugs, biologicals, and radiopharmaceuticals, regardless of cost, except those drugs with pass-through payment status and SADs, unless they function as packaged supplies (78 FR 74868, 74869, and 74909 and 79 FR 66800)

PMID 2899993

We proposed to require ASCs to offer all patients meeting the measure's denominator specifications the opportunity to complete the survey and to report on all completed surveys received